Related references
Note: Only part of the references are listed.Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
Lana E. Kandalaft et al.
ONCOIMMUNOLOGY (2013)
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
Osama E. Rahma et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
Christina S. Chu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
Ronald J. deLeeuw et al.
CLINICAL CANCER RESEARCH (2012)
Interleukin 2 in Cancer Therapy
G. K. Antony et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
Soyoung Baek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
Lotte Engell-Noerregaard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
Jung Han Kim et al.
CLINICAL IMMUNOLOGY (2007)
Taking dendritic cells into medicine
Ralph M. Steinman et al.
NATURE (2007)
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
M Ahmadzadeh et al.
BLOOD (2006)
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
GC Cesana et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sequential development of interleukin 2 dependent effector and regulatory T cells in response to endogenous systemic antigen
B Knoechel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression
T Hiura et al.
JOURNAL OF IMMUNOLOGY (2005)
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2
PA Antony et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients
SK Kassim et al.
CLINICAL BIOCHEMISTRY (2004)
Immunological treatment of ovarian cancer
MJ Cannon et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2004)
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells
S Paczesny et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Share Paper
